<DOC>
	<DOCNO>NCT02140281</DOCNO>
	<brief_summary>A study evaluate effect repeat oral dos AZD1722 pharmacokinetics Cefadroxil</brief_summary>
	<brief_title>To Assess Effect AZD1722 Pharmacokinetics Cefadroxil Healthy Volunteers</brief_title>
	<detailed_description>A Phase 1 , Single-center , Randomized , 2-Way Cross-over , Open-label Study Evaluate Effect Oral Repeated Doses AZD1722 Pharmacokinetics Oral Cefadroxil Healthy Volunteers</detailed_description>
	<mesh_term>Cefadroxil</mesh_term>
	<criteria>1 . Healthy male female volunteer age ≥18 year ≤50 year ( inclusive ) suitable vein cannulation repeat venepuncture 2 . Females could nonchildbearing potential child bear potential Females nonchild bear potential Postmenopausal , documentation irreversible surgical sterilization hysterectomy , bilateral oophorectomy bilateral salpingectomy tubal ligation . Females childbearing potential must negative pregnancy test screening must lactate , use one follow effective method avoid pregnancy treatment period , must establish use oral , injected , implanted hormonal method contraception , placement intrauterine device ( IUD ) intrauterine system , use barrier method contraception : condom occlusive cap ( diaphragm cervical/vault cap ) spermicidal . Male healthy volunteer partner childbearing potential must agree avoid father child , refrain donate sperm , first day dose least 3 month last dose investigational product , therefore either sterile ( appropriate postvasectomy documentation absence sperm ejaculate ) agree use , one follow approve method contraception : male condom spermicide ; sterile sexual partner use female sexual partner acceptable form effective contraception ( see ) 3 . Have body mass index ( BMI ) ≥18 ≤30 kg/m2 weigh least 50 kg 100 kg 1.History clinically significant disease disorder , opinion principal investigator , may either put healthy volunteer risk participation study , influence result healthy volunteer 's ability participate study . 2.History presence GI , hepatic renal disease include GI surgery appendectomy condition know interfere absorption , distribution , metabolism excretion drug . 3.Any clinically significant illness , medical/surgical procedure trauma within 4 week first administration investigational product . 3 History severe allergy/hypersensitivity ongoing allergy/hypersensitivity , judge principal investigator history hypersensitivity drug similar chemical structure class AZD1722 cefadroxil . 4 . Has receive another new chemical entity ( define compound approve marketing ) participate clinical study include drug treatment within least 30 day first administration investigational product study . 5 . Loose stool ≥2 day past 7 day investigational product administration . Use medication know affect stool consistency and/or GI motility , include fibre supplement , anti diarrheals , prokinetic drug , enema , probiotic medication supplement ; salt electrolyte supplement contain sodium , potassium , chloride , bicarbonate formulation past 7 day randomization</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Phase I , Healthy Volunteers</keyword>
</DOC>